K. Phan

发表

Pembrolizumab for PD-L1-Positive Breast Cancer Refractory to Chemotherapy.

M. Charif, K. Phan, K. Phan, 2020, American journal of therapeutics.

The incidence of second primary malignancies after gastrointestinal stromal tumor before and after the introduction of imatinib mesylate

David E. Kurlander, K. Martires, Marin F. Xavier, 2013 .

Generalization optimizing machine learning to improve CT scan radiomics and assess immune checkpoint inhibitors’ response in non-small cell lung cancer: a multicenter cohort study

F. Rybicki, D. Huntsman, F. Chandelier, 2023, Frontiers in oncology.